Home \ Antibodies \ Oxidized phospholipids, Mouse, clone 10C12
Catalog # HM1142

Oxidized phospholipids, Mouse, clone 10C12

Oxidized phospholipids (OxPL), such as oxidized PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine) and its derivates (POVPC and PGPC) are the biologically active components of minimally oxidized LDL. The anti-OxPL antibody HM1142 is able to recognize the OxPL derivates POVPC and PGPC.

Read more
Please choose the quantity of items you wish to add to your cart…
Find distributor

Oxidized phospholipids (OxPL), such as oxidized PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine) and its derivates (POVPC and PGPC) are the biologically active components of minimally oxidized LDL. Both fragmented and full-length oxygenated molecules can regulate immune reactions including the activation of inflammation. Pro-inflammatory effects of OxPL include stimulation of endothelial cells to bind monocytes and induction of tissue clotting factor, IL-8, MCP-1, G-CSF and other mediators of atherothrombosis. Anti-inflammatory effects of OxPL are mediated by induction of protective enzymes such as heme oxygenase-1 as well as suppression of innate immune responses to bacterial lipopolysaccharide (LPS) due to inhibition of LPS recognition by LPS-binding protein (LBP) and CD14. It is well-known that oxidized phospholipids play, as immune modulators, an important role in cardiovascular diseases such as atherosclerosis. However, these lipid oxidation products have been suggested to also play a role in many other disease settings. Lipid oxidation products accumulate in inflamed and oxidative damaged tissue, where they are derived from oxidative modification of lipoproteins, but also from membranes of cells undergoing apoptosis. Increased oxidative stress as well as decreased clearance of apoptotic cells has been implied to contribute to accumulation of OxPL in chronically inflamed tissues. It is therefore suggested that OxPLs are also associated with other diseases associated with dyslipidemia such as diabetes, metabolic syndrome, renal insufficiency and fatty liver disease. In addition, in organs which are constantly exposed to oxidative stress, including lung, skin, and eyes, increased levels of OxPL are suggested to contribute to inflammatory conditions. In theory, treatment with OxPL neutralizing antibodies can be used to prevent or reverse these diseases. The anti-OxPL antibody HM1142 is able to recognize the OxPL derivates POVPC and PGPC.

Functional studies, Immuno assays, Paraffin sections, Western blot

Application Notes
- FS: antibody 10C12 demonstrated potent OxPL neutralizing activity in vitro and the ability to inhibit macrophage accumulation within arteries of Apoe–/– mice fed a Western diet for 4 weeks. 10C12 treatment caused a 40% decrease in lipid accumulation within aortas of secreted IgM deficient, sIgM–/–Apoe–/–, mice fed a low-fat diet, when the antibody was administrated between 32-40 weeks of age. (Ref.1).
- IHC-P: Staining was done on 5 μm crosssections of human autopsy samples using 10C12 (Ref.1).

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Product type
Monoclonal antibodies
100 µg, 20 µg
0.2 µm filtered in PBS+0.1%BSA
Immunogen POVPC/PGPC (OxPL)
Mouse IgM
Cross reactivity
Human – Yes
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
CoA-TDS HM1067-HM2099 Safety Data Sheet

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us